Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients

Kenneth R. Meehan, Rebecca Slack, Edmund Gehan, Herbert B. Herscowitz, Ellen M. Areman, Mark Ebadi, Mitchell S. Cairo, Marc E Lippman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Preclinical studies have demonstrated the rapid and efficient mobilization of hematopoietic peripheral blood stem cells (PBSC) in a mouse model using the combination of paclitaxel with recombinant human granulocyte colony-stimulating factor (rhG-CSF). On the basis of these results, a clinical trial was initiated using rhG-CSF with paclitaxel for PBSC mobilization in high-risk breast cancer patients. The mobilized PBSC were evaluated for CD34+ cell number, mononuclear cell content, and clonogenic potential. One-hundred and seventeen breast cancer patients received paclitaxel (300 mg/m2) administered as a 24-h continuous intravenous infusion. Forty-eight hours after completing paclitaxel, rhG-CSF (5 μg/kg) was initiated and continued until completion of PBSC collection. Leukapheresis was initiated once the white blood cell count reached 1.0 × 109/L. Each collection was evaluated for the numbers of mononuclear cells (MNC) and CD34+ cells. Clonogenic potential was enumerated using colony-forming units-granulocyte-macrophage (CFU-GM) and burst-forming units-erythroid (BFU-E). Patients receiving paclitaxel with rhG-CSF mobilized a large number of mononuclear cells/apheresis (mean, 3.7 × 108; range, 3.3-4.1) and CD34+ cells/apheresis (mean, 7.2 × 106; range, 6.1-8.4). The average number of leukophereses needed was 1.8 (mean, range 1.6-2.0). Colony growth was normal with 178.9 × 105 and 214.8 × 105 colonies counted in CFU-GM and BFU-E assays, respectively. Patients engrafted platelets and neutrophils on day 10 following transplantation. In conclusion, PBSC mobilization with paclitaxel and rhG-CSF results in a large number of mononuclear cells and CD34+ cells with normal clonogenic potential. The cells engraft normally following high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer patients. These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients.

Original languageEnglish
Pages (from-to)415-421
Number of pages7
JournalJournal of Hematotherapy and Stem Cell Research
Volume11
Issue number2
DOIs
StatePublished - Apr 25 2002
Externally publishedYes

Fingerprint

Granulocyte Colony-Stimulating Factor
Paclitaxel
Breast Neoplasms
Cell Count
Hematopoietic Stem Cell Mobilization
Leukapheresis
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Blood Component Removal
Stem Cell Transplantation
Hematopoietic Stem Cells
Peripheral Blood Stem Cells
Leukocyte Count
Intravenous Infusions
Neutrophils
Blood Platelets
Transplantation
Clinical Trials
Drug Therapy
Growth

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients. / Meehan, Kenneth R.; Slack, Rebecca; Gehan, Edmund; Herscowitz, Herbert B.; Areman, Ellen M.; Ebadi, Mark; Cairo, Mitchell S.; Lippman, Marc E.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 11, No. 2, 25.04.2002, p. 415-421.

Research output: Contribution to journalArticle

Meehan, KR, Slack, R, Gehan, E, Herscowitz, HB, Areman, EM, Ebadi, M, Cairo, MS & Lippman, ME 2002, 'Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients', Journal of Hematotherapy and Stem Cell Research, vol. 11, no. 2, pp. 415-421. https://doi.org/10.1089/152581602753658600
Meehan, Kenneth R. ; Slack, Rebecca ; Gehan, Edmund ; Herscowitz, Herbert B. ; Areman, Ellen M. ; Ebadi, Mark ; Cairo, Mitchell S. ; Lippman, Marc E. / Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients. In: Journal of Hematotherapy and Stem Cell Research. 2002 ; Vol. 11, No. 2. pp. 415-421.
@article{29a47c22f8f5444eb931b68784d96119,
title = "Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients",
abstract = "Preclinical studies have demonstrated the rapid and efficient mobilization of hematopoietic peripheral blood stem cells (PBSC) in a mouse model using the combination of paclitaxel with recombinant human granulocyte colony-stimulating factor (rhG-CSF). On the basis of these results, a clinical trial was initiated using rhG-CSF with paclitaxel for PBSC mobilization in high-risk breast cancer patients. The mobilized PBSC were evaluated for CD34+ cell number, mononuclear cell content, and clonogenic potential. One-hundred and seventeen breast cancer patients received paclitaxel (300 mg/m2) administered as a 24-h continuous intravenous infusion. Forty-eight hours after completing paclitaxel, rhG-CSF (5 μg/kg) was initiated and continued until completion of PBSC collection. Leukapheresis was initiated once the white blood cell count reached 1.0 × 109/L. Each collection was evaluated for the numbers of mononuclear cells (MNC) and CD34+ cells. Clonogenic potential was enumerated using colony-forming units-granulocyte-macrophage (CFU-GM) and burst-forming units-erythroid (BFU-E). Patients receiving paclitaxel with rhG-CSF mobilized a large number of mononuclear cells/apheresis (mean, 3.7 × 108; range, 3.3-4.1) and CD34+ cells/apheresis (mean, 7.2 × 106; range, 6.1-8.4). The average number of leukophereses needed was 1.8 (mean, range 1.6-2.0). Colony growth was normal with 178.9 × 105 and 214.8 × 105 colonies counted in CFU-GM and BFU-E assays, respectively. Patients engrafted platelets and neutrophils on day 10 following transplantation. In conclusion, PBSC mobilization with paclitaxel and rhG-CSF results in a large number of mononuclear cells and CD34+ cells with normal clonogenic potential. The cells engraft normally following high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer patients. These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients.",
author = "Meehan, {Kenneth R.} and Rebecca Slack and Edmund Gehan and Herscowitz, {Herbert B.} and Areman, {Ellen M.} and Mark Ebadi and Cairo, {Mitchell S.} and Lippman, {Marc E}",
year = "2002",
month = "4",
day = "25",
doi = "10.1089/152581602753658600",
language = "English",
volume = "11",
pages = "415--421",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients

AU - Meehan, Kenneth R.

AU - Slack, Rebecca

AU - Gehan, Edmund

AU - Herscowitz, Herbert B.

AU - Areman, Ellen M.

AU - Ebadi, Mark

AU - Cairo, Mitchell S.

AU - Lippman, Marc E

PY - 2002/4/25

Y1 - 2002/4/25

N2 - Preclinical studies have demonstrated the rapid and efficient mobilization of hematopoietic peripheral blood stem cells (PBSC) in a mouse model using the combination of paclitaxel with recombinant human granulocyte colony-stimulating factor (rhG-CSF). On the basis of these results, a clinical trial was initiated using rhG-CSF with paclitaxel for PBSC mobilization in high-risk breast cancer patients. The mobilized PBSC were evaluated for CD34+ cell number, mononuclear cell content, and clonogenic potential. One-hundred and seventeen breast cancer patients received paclitaxel (300 mg/m2) administered as a 24-h continuous intravenous infusion. Forty-eight hours after completing paclitaxel, rhG-CSF (5 μg/kg) was initiated and continued until completion of PBSC collection. Leukapheresis was initiated once the white blood cell count reached 1.0 × 109/L. Each collection was evaluated for the numbers of mononuclear cells (MNC) and CD34+ cells. Clonogenic potential was enumerated using colony-forming units-granulocyte-macrophage (CFU-GM) and burst-forming units-erythroid (BFU-E). Patients receiving paclitaxel with rhG-CSF mobilized a large number of mononuclear cells/apheresis (mean, 3.7 × 108; range, 3.3-4.1) and CD34+ cells/apheresis (mean, 7.2 × 106; range, 6.1-8.4). The average number of leukophereses needed was 1.8 (mean, range 1.6-2.0). Colony growth was normal with 178.9 × 105 and 214.8 × 105 colonies counted in CFU-GM and BFU-E assays, respectively. Patients engrafted platelets and neutrophils on day 10 following transplantation. In conclusion, PBSC mobilization with paclitaxel and rhG-CSF results in a large number of mononuclear cells and CD34+ cells with normal clonogenic potential. The cells engraft normally following high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer patients. These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients.

AB - Preclinical studies have demonstrated the rapid and efficient mobilization of hematopoietic peripheral blood stem cells (PBSC) in a mouse model using the combination of paclitaxel with recombinant human granulocyte colony-stimulating factor (rhG-CSF). On the basis of these results, a clinical trial was initiated using rhG-CSF with paclitaxel for PBSC mobilization in high-risk breast cancer patients. The mobilized PBSC were evaluated for CD34+ cell number, mononuclear cell content, and clonogenic potential. One-hundred and seventeen breast cancer patients received paclitaxel (300 mg/m2) administered as a 24-h continuous intravenous infusion. Forty-eight hours after completing paclitaxel, rhG-CSF (5 μg/kg) was initiated and continued until completion of PBSC collection. Leukapheresis was initiated once the white blood cell count reached 1.0 × 109/L. Each collection was evaluated for the numbers of mononuclear cells (MNC) and CD34+ cells. Clonogenic potential was enumerated using colony-forming units-granulocyte-macrophage (CFU-GM) and burst-forming units-erythroid (BFU-E). Patients receiving paclitaxel with rhG-CSF mobilized a large number of mononuclear cells/apheresis (mean, 3.7 × 108; range, 3.3-4.1) and CD34+ cells/apheresis (mean, 7.2 × 106; range, 6.1-8.4). The average number of leukophereses needed was 1.8 (mean, range 1.6-2.0). Colony growth was normal with 178.9 × 105 and 214.8 × 105 colonies counted in CFU-GM and BFU-E assays, respectively. Patients engrafted platelets and neutrophils on day 10 following transplantation. In conclusion, PBSC mobilization with paclitaxel and rhG-CSF results in a large number of mononuclear cells and CD34+ cells with normal clonogenic potential. The cells engraft normally following high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer patients. These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0036223616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036223616&partnerID=8YFLogxK

U2 - 10.1089/152581602753658600

DO - 10.1089/152581602753658600

M3 - Article

VL - 11

SP - 415

EP - 421

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 2

ER -